Key Takeaways
- • Eli Lilly achieved a 34.99% profit margin with $20.64 billion in net income for FY25, positioning it as one of the most profitable blue-chip stocks among hedge fund holdings.
- • The company briefly crossed a $1 trillion market capitalization on November 21, 2025, becoming the first healthcare company ever to reach this milestone, with stock gains of 36.2% in 2025 driven primarily by GLP-1 drug market dominance over Novo Nordisk.
- • Q1 2026 revenue surged 56% year-over-year to $19.8 billion, significantly exceeding mean analyst estimates and demonstrating accelerating earnings momentum in diabetes and obesity therapeutics.
- • FDA approved a new maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz) on June 9, 2026, reducing injections to six per year for atopic dermatitis patients, while multiple diabetes and obesity drug candidates (Foundayo, retatrutide) delivered positive Phase 3 trial data in early June 2026.
- • Jefferies raised its price target to $1,350 from $1,330 with a "Buy" rating following strong clinical trial readouts, with analysts projecting 9.20% additional upside despite the stock's premium valuation relative to the broader pharmaceutical sector.
Summary
Eli Lilly has solidified its position as a top institutional investment choice, combining exceptional profitability metrics with dominant market positioning in high-growth therapeutic areas. The company reported a profit margin of 34.99% and net income of $20.64 billion in fiscal 2025, earning it a place among the most profitable blue-chip stocks favored by hedge funds. This profitability profile reflects both operational excellence and Lilly's commanding share of the rapidly expanding GLP-1 drug market for diabetes and obesity treatment, where it has outpaced competitor Novo Nordisk.
The stock's valuation milestone underscores investor appetite for Lilly's growth trajectory. The company briefly achieved a $1 trillion market capitalization on November 21, 2025, marking the first time any healthcare company reached this valuation threshold. Stock appreciation of 36.2% in 2025 was predominantly driven by Lilly's GLP-1 market dominance. Most recent performance data shows accelerating momentum: Q1 2026 revenue increased 56% year-over-year to $19.8 billion, substantially exceeding consensus analyst estimates and demonstrating sustained demand acceleration across the company's drug portfolio.
Recent regulatory and clinical developments in June 2026 have further validated the investment thesis. On June 9, Lilly received FDA approval for a new maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing a single 250 mg injection every eight weeks for atopic dermatitis patients, reducing annual maintenance injections to six. Simultaneously, the company achieved positive trial outcomes across its diabetes and obesity pipeline: Foundayo (orforglipron) outperformed oral semaglutide on A1C reduction and weight loss in the ACHIEVE-3 trial, while retatrutide demonstrated substantial weight loss alongside improvements in knee osteoarthritis, sleep apnea, and A1C levels in Phase 3 obesity and type 2 diabetes studies.
These developments prompted Jefferies to raise its price target to $1,350 from $1,330, maintaining a "Buy" rating. The analyst firm noted that observed safety profiles were manageable and that retatrutide's competitive positioning would be difficult for competitors to match in large-scale obesity trials. Despite Lilly commanding a premium valuation relative to the broader pharmaceutical sector, analysts project an additional 9.20% upside, reflecting confidence in the company's ability to sustain revenue growth and market share expansion in obesity and diabetes therapeutics over the medium term.
The stock's valuation milestone underscores investor appetite for Lilly's growth trajectory. The company briefly achieved a $1 trillion market capitalization on November 21, 2025, marking the first time any healthcare company reached this valuation threshold. Stock appreciation of 36.2% in 2025 was predominantly driven by Lilly's GLP-1 market dominance. Most recent performance data shows accelerating momentum: Q1 2026 revenue increased 56% year-over-year to $19.8 billion, substantially exceeding consensus analyst estimates and demonstrating sustained demand acceleration across the company's drug portfolio.
Recent regulatory and clinical developments in June 2026 have further validated the investment thesis. On June 9, Lilly received FDA approval for a new maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing a single 250 mg injection every eight weeks for atopic dermatitis patients, reducing annual maintenance injections to six. Simultaneously, the company achieved positive trial outcomes across its diabetes and obesity pipeline: Foundayo (orforglipron) outperformed oral semaglutide on A1C reduction and weight loss in the ACHIEVE-3 trial, while retatrutide demonstrated substantial weight loss alongside improvements in knee osteoarthritis, sleep apnea, and A1C levels in Phase 3 obesity and type 2 diabetes studies.
These developments prompted Jefferies to raise its price target to $1,350 from $1,330, maintaining a "Buy" rating. The analyst firm noted that observed safety profiles were manageable and that retatrutide's competitive positioning would be difficult for competitors to match in large-scale obesity trials. Despite Lilly commanding a premium valuation relative to the broader pharmaceutical sector, analysts project an additional 9.20% upside, reflecting confidence in the company's ability to sustain revenue growth and market share expansion in obesity and diabetes therapeutics over the medium term.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.